ClinicalTrials.gg
RecruitingNCT01745237Updated Oct 16, 2026

Prognostic Value of Clinical Cardiovascular MRI

An observational study in Sarcoidosis, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Sep 2002; still recruiting 24 years 2 months later.
Updated Oct 16, 2026Eligibility revisedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
27,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.

Planned enrollment
Largest of 46
27,000 · median 200
Started
2002
the only one that year
Observational
46 of 115
14 open now
Primary completion
2032-06
later than 22 of 24 live
Registered
40th of 115
by date
Lead sponsor
4 of 115
Duke University

Among the 115 studies in Sarcoidosis with a site in United States, this one has the largest planned enrollment of the 46 observational ones that give a count, is the only one that started in 2002, is one of 46 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 40th registered.

Sarcoidosis

271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.

Browse Sarcoidosis studies →

Open to participants now

23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Sarcoidosis studies recruiting now, 30 (73%) set no upper age limit and 1 (2%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Sarcoidosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to identify findings on cardiovascular MR imaging (CMR) that are specific to various cardiac or vascular disorders in patients undergoing routine CMR scans.

Read the detailed description

The objectives of this study are to 1) compare the information on your CMR scan to other clinical tests that you have undergone; and 2) determine whether the results of the CMR scan are predictive of future events related to heart or circulatory problems..

03

Conditions studied

  • Sarcoidosis

Browse trials for

Keywords

  • Sarcoidosis
  • Cardiac Magnetic Resonance
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults referred for routine CMR scans

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled to undergo routine clinical CMR scan

Exclusion criteria

Exclusion Criteria:

  • to MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
27,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. cardiac mortality

    Time frame: > 1year

  2. arrhythmic death

    Time frame: > 1year

  3. Pulmonary mortality

    only in subset of patients with pulmonary sarcoidosis

    Time frame: > 1year

Secondary outcomes

  1. all-cause mortality

    Time frame: > 1year

  2. arrhythmic events

    Time frame: > 1year

  3. Pulmonary Transplant

    Time frame: > 1 year

  4. Cardiac Transplant

    Time frame: > 1 year

  5. PPM placement/high grade AV block

    Time frame: > 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352. Epub 2009 Nov 2. PubMed 19884472 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2002 (actual). Primary completion is estimated for Jun 2032, 357 months after the start.

Of 59 non-industry observational studies under Sarcoidosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 111. This study's planned 357 months is above that.

Counting every sponsor, half of 59 studies reached it within 49 months; a quarter within 20 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2012
First posted
Dec 10, 2012
StartActual
Sep 2002
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedBiopsy proven sarcoidosis
  • RemovedSuspected cardiac sarcoidosis
  • AddedScheduled to undergo routine clinical CMR scan
Oct 16, 2026
Title
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis→Prognostic Value of Clinical Cardiovascular MRI
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Eligibility 1 inclusion criterion added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedBiopsy proven sarcoidosis
    • RemovedSuspected cardiac sarcoidosis
    • AddedScheduled to undergo routine clinical CMR scan
    Title Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis→Prognostic Value of Clinical Cardiovascular MRI
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01745237
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Dec 10, 2012
Start date
Sep 2002
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Oct 16, 2026

Study contacts

Han W Kim, MD
Contact
kim00050@duke.edu
919-668-3539
Raymond J. Kim, MD
Contact
kim00049@duke.edu
919-668-3539
Raymond J Kim, MD
principal investigator · Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion